

Selected References for Deruxtecan ADC and Albumin based Drug Delivery.

1. Takashi Nakada, et al. Novel antibody-drug conjugates containing exatecan derivative-based cytotoxic payloads. *Bioorg. Med. Chem. Lett.* 2016; 26:1542–1545.
Highlight: Developed Exatecan derivative-based payloads for ADCs with potent antitumor activity and stable linker technology.
2. Yusuke Ogitani, et al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. *Cancer Sci.* 2016;107(7):1039–1046.
Highlight: Demonstrated the bystander killing effect of DS-8201a in HER2-heterogeneous tumors.
3. Naoki Takegawa, et al. DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance. *Int. J. Cancer.* 2017; 141:1682–1689.
Highlight: Showed that DS-8201a overcomes T-DM1 resistance in HER2-positive gastric cancer models.
4. Ella N. Hoogenboezem, et al. Harnessing Albumin as a Carrier for Cancer Therapies. *Adv. Drug Deliv. Rev.* 2018; 130:144–175.
Highlight: Reviewed albumin-based drug delivery and albumin-drug conjugate strategies for cancer therapeutics.